In downtown Austin this week, psychedelic medicine is not a fringe topic; it is a marquee attraction. As SXSW fills hotel ballrooms with talk of psilocybin and ibogaine, Texas lawmakers are backing a $50 million state play on ibogaine research, and a major biotech just logged late-stage wins for a psilocybin therapy. The conversation now runs straight from festival stages to the Capitol and into clinics where patients are already looking for care.
At SXSW: panels on access and research
On Monday and Wednesday at SXSW, sessions including "Psychedelics: the Paradigm-Changing Future of Mental Health" and "Expediting Psychedelic Research to Qualify for Right to Try" are set to bring together industry figures and mental health advocates. Scheduled speakers include Compass Pathways' Dr. Steve Levine, Mental Health America's Dr. Jessica Jackson, and veterans' advocates who say some service members have already gone to Mexico for treatment. As reported by The Austin Chronicle, the sessions are designed to dig into how research, policy, and clinical practice might actually line up in the real world.
Clinical trial momentum
Biotech watchers took notice when Compass Pathways announced it had met the primary endpoint in its second Phase 3 COMP006 trial, giving the company two positive late-stage studies of its COMP360 psilocybin formulation for treatment-resistant depression. In a press release, Compass said a 25 mg dose produced a clinically meaningful reduction in depression scores and that it "expects to complete an NDA submission in Q4 (2026)." The company also said it has asked the FDA for a meeting to discuss a rolling submission and review. In a Feb. 17 statement, Compass Pathways laid out topline results along with the next steps, and Compass Pathways published the data and projected timeline.
Veterans, ibogaine and Mexico
For some veterans, the experimental future is already a plane ticket away. A cohort of about 30 special-operations veterans traveled to a medical clinic in Mexico for magnesium-protected ibogaine treatment and later showed large reductions in PTSD, depression, and disability scores, according to a report in Nature Medicine. Researchers and clinical guidelines note that ibogaine can trigger a prolonged, oneirogenic experience that may last more than 24 hours, and the drug has been linked to cardiac risks, which is why screening and cardiac monitoring sit at the center of published treatment protocols. Nature Medicine summarizes those early observational findings.
Texas' $50M bet
At the state level, policy has been racing to keep up. Gov. Greg Abbott signed Senate Bill 2308, creating a psychedelic research consortium and authorizing roughly $50 million in state matching funds to support FDA-approved ibogaine clinical trials and related infrastructure. Texas officials say the money is meant to be paired with private investment and university partners to launch multi-year trials rather than one-off experiments. Coverage from The Texas Tribune details how the program is structured and who has lined up in public support.
Regulatory friction and Right to Try
Federal rules still throw sand in the gears. Ibogaine is listed as a Schedule I substance under federal regulations (21 CFR §1308.11), which sharply limits clinical use outside tightly controlled research settings. Advocates point to the Freedom to Heal Act, a bipartisan bill introduced in December 2025, as one possible workaround. The proposal would create a DEA registration process that could let physicians treat certain Right-to-Try eligible patients with Schedule I investigational drugs under close supervision. The federal regulatory listing for ibogaine appears in the Code of Federal Regulations, and the Freedom to Heal Act text is posted on Congress.gov.
What to watch
In the months ahead, the action to watch breaks into two tracks. One is whether Texas-backed public-private trials move from the planning stage into actual patient enrollment. The other is how aggressively companies push a regulatory pathway for psilocybin-based therapies. Compass Pathways' timeline points to an NDA submission push in Q4 (2026), while state grants and university partnerships in Texas could generate exactly the kind of safety data regulators will expect to see on ibogaine. The SXSW sessions on Monday and Wednesday will serve as a live stress test of how veterans, clinicians, and investors are lining up around both the risks and the upside of psychedelic therapies, and could help steer the next round of public policy moves in Austin and beyond. For program listings and session specifics, see Real Chemistry and related festival coverage.
